What is TearSolutions?
TearSolutions is a specialized biotechnology firm focused on the development of innovative therapies for ocular surface diseases. Its flagship product, Lacripep, represents a first-in-class peptide therapy designed to restore ocular surface health by addressing specific tear protein deficiencies. This approach is particularly critical for patients suffering from chronic conditions such as primary Sjogren's Syndrome and dry eye disease, a condition that disproportionately affects aging populations and is increasingly influenced by environmental stressors. By targeting the underlying biological mechanisms of these diseases, TearSolutions distinguishes itself from traditional palliative treatments, positioning its pipeline as a high-value asset in the global ophthalmology market.
How much funding has TearSolutions raised?
TearSolutions has raised a total of $23.9M across 5 funding rounds:
Series A
$3M
Private Equity
$3.4M
Private Equity
$8.1M
Debt
$6.4M
Series B
$3M
Series A (2015): $3M with participation from LaunchCapital, CIT, and Santen Pharmaceuticals Co., Ltd.
Private Equity (2017): $3.4M, investors not publicly disclosed
Private Equity (2017): $8.1M, investors not publicly disclosed
Debt (2019): $6.4M featuring Medarva Foundation, UVa Seed Fund, VTC Innovation Fund, and PharmStandard Ventures
Series B (2024): $3M, investors not publicly disclosed
Key Investors in TearSolutions
LaunchCapital
LaunchCapital is a venture capital firm that supports entrepreneurs at the seed and early stages, providing hands-on assistance from the very beginning.
CIT
The Center for Innovative Technology (CIT) creates technology-based economic development strategies to assist in the next generation of technology and technology companies.
Santen Pharmaceuticals Co., Ltd.
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company specializing in ophthalmology with a global footprint in over 50 countries.
What's next for TearSolutions?
With the successful closure of this major enterprise-level funding, TearSolutions is poised to transition into a critical phase of clinical validation and commercial preparation. The strategic allocation of these funds will likely prioritize the advancement of ongoing clinical trials for Lacripep, ensuring the data integrity required for regulatory submissions. Furthermore, the company is expected to scale its operational infrastructure to support potential market entry. As the firm continues to navigate the complex landscape of ocular therapeutics, its focus will remain on demonstrating the clinical efficacy of its peptide-based platform, thereby creating significant value for stakeholders and addressing the unmet medical needs of patients worldwide.
See full TearSolutions company page
